Safety and Tolerability of Empagliflozin (Jardiance)

1
.
Safety and Tolerability of Empagliflozin (Jardia
nce) Anwer Ghani FIBMS Iraq
2
.
Empagliflozin is a sodiumglucose cotransporter
(linked transporter) 2 inhibitor (SGLT2)
inhibitor. It inhibits glucose reabsorption in
renal tubules and increase urinary glucose
excretion. The glycosuria is dose dependent.
3
.
SGLT2 demonstrated significant cardiovascular
benefits making them attractive options for the
management of Type 2 diabetes mellitus (T2DM).
4
.
The incidence of any AEs, AEs leading to
treatment discontinuation, severe AEs, and
serious AEs was similar to other treatment. A
study.
5
.
The empagliflozin 10/25 mg group was not
associated with a higher rate of confirmed
hypoglycemia versus placebo. A study.
6
(No Transcript)
7
.
The incidence of events consistent with urinary
tract infections (UTI) was also similar for the
empagliflozin 10/25 mg group versus placebo (9.27
vs. 9.70/100 patient-years, respectively). Many
studies.
8
.
History of UTI was identified as a risk factor
for UTI during treatment.
9
.
Events consistent with genital infections
occurred more frequently with empagliflozin 10/25
mg than placebo (3.54 vs. 0.95/100 patient-years,
respectively).
10
.
The frequency of AEs consistent with volume
depletion was similar across groups, but higher
with empagliflozin 10/25 mg than placebo in
patients aged 75 years and those on loop
diuretics at baseline. A study.
11
.
Compared with DPP-4 inhibitors and GLP-1
agonists, SGLT-2 inhibitors were not associated
with excess risk for severe UTIs (defined as
hospitalization for UTI, sepsis with UTI, or
pyelonephritis) or for outpatient UTIs. A very
big study.
12
.
Sodiumglucose cotransporter 2 inhibitors reduce
the risk of hospitalization for heart failure in
patients with heart failure ( reduced or
preserved ejection fraction).